Neurizon Therapeutics (ASX:NUZ) reported positive results from a preclinical study of its lead drug candidate, NUZ-001, for Amyotrophic Lateral Sclerosis (ALS), according to a Friday filing with the Australian bourse.
NUZ-001 was shown to prevent the aggregation of TAR DNA-binding protein 43 (TDP-43), a driver of ALS pathology, the filing said.
The drug candidate also improved the electrophysiological dysfunction of TDP-43 aggregation in M337V Motor Neurons. The TDP-43 M337V mutation impairs neuronal electrical activity at multiple levels.
The company plans to conduct its clinical trial of NUZ-001 early next year, Chief Executive Michael Thurn said in the filing.
Company shares fell 4% in recent Monday trade.
Price (AUD): $0.19, Change: $-0.01, Percent Change: -4.00%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.